{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:05:13Z","timestamp":1788786313790,"version":"build-2803163510"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontierspartnerships.org"],"crossmark-restriction":true},"short-container-title":["Transpl Int"],"abstract":"<jats:p>Nirmatrelvir\/ritonavir is a promising option for preventing severe COVID-19 in solid organ transplant recipients with SARS-CoV-2 infection. However, concerns have arisen regarding potential drug interactions with calcineurin inhibitors (CNI). This two-phase multicentre retrospective study, involving 113 patients on tacrolimus and 13 on cyclosporine A, aimed to assess the feasibility and outcomes of recommendations issued by The French societies of transplantation (SFT) and pharmacology (SFPT) for CNI management in this context. The study first evaluated adherence to recommendations, CNI exposure, and clinical outcomes. Notably, 96.5% of patients on tacrolimus adhered to the recommendations, maintaining stable tacrolimus trough concentrations (C<jats:sub>0<\/jats:sub>) during nirmatrelvir\/ritonavir treatment. After reintroduction, most patients experienced increased C<jats:sub>0<\/jats:sub>, with 42.9% surpassing 15\u00a0ng\/mL, including three patients exceeding 40\u00a0ng\/mL. Similar trends were observed in cyclosporine A patients, with no COVID-19-related hospitalizations. Moreover, data from 22 patients were used to refine the reintroduction strategy. Modelling analyses suggested reintroducing tacrolimus at 50% of the initial dose on day 8, and then at 100% from day 9 as the optimal approach. In conclusion, the current strategy effectively maintains consistent tacrolimus exposure during nirmatrelvir\/ritonavir treatment, and a stepwise reintroduction of tacrolimus may be better suited to the low CYP3A recovery.<\/jats:p>","DOI":"10.3389\/ti.2024.12360","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T04:11:23Z","timestamp":1711426283000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Adaptative Strategy of Immunosuppressive Drugs Dosage Adjustments When Combined With Nirmatrelvir\/Ritonavir in Solid Organ Transplant Recipients With COVID-19"],"prefix":"10.3389","volume":"37","author":[{"given":"Lidvine","family":"Boland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Devresse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Monchaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Briol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Belaiche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptiste","family":"Giguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Couzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Thaunat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Meszaros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Roussoulieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Haufroid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Le Meur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Lemaitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,26]]},"reference":[{"key":"B1","volume-title":"NIH COVID-19 Treatment Guidelines","year":"2024"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults With Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/FTD.0000000000001014","article-title":"Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir\/Ritonavir in Patients With COVID-19","volume":"45","author":"Lemaitre","year":"2022","journal-title":"Ther Drug Monit"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/j.transproceed.2022.04.015","article-title":"Paxlovid (Nirmatelvir\/Ritonavir) and Tacrolimus Drug-Drug Interaction in a Kidney Transplant Patient With SARS-2-CoV Infection: A Case Report","volume":"54","author":"Prikis","year":"2022","journal-title":"Transplant Proc"},{"key":"B5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12882-023-03154-w","article-title":"Nirmatrelvir\/Ritonavir Treatment in SARS-CoV-2 Positive Kidney Transplant Recipients \u2013 A Case Series With Four Patients","volume":"24","author":"Schneider","year":"2023","journal-title":"BMC Nephrol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1111\/ajt.17027","article-title":"Early Clinical Experience With Nirmatrelvir\/Ritonavir for the Treatment of COVID-19 in Solid Organ Transplant Recipients","volume":"22","author":"Salerno","year":"2022","journal-title":"Am J Transplant"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1111\/ajt.16955","article-title":"Nirmatrelvir\/Ritonavir Use: Managing Clinically Significant Drug-Drug Interactions With Transplant Immunosuppressants","volume":"22","author":"Lange","year":"2022","journal-title":"Am J Transplant"},{"key":"B8","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.therap.2022.03.005","article-title":"Management of Drug-Drug Interactions With Nirmatrelvir\/Ritonavir in Patients Treated for Covid-19: Guidelines From the French Society of Pharmacology and Therapeutics (SFPT)","volume":"77","author":"Lemaitre","year":"2022","journal-title":"Therapies"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s40262-022-01158-7","article-title":"Yes We Can (Use Nirmatrelvir\/Ritonavir Even in High Immunological Risk Patients Treated With Immunosuppressive Drugs)","volume":"61","author":"Lemaitre","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"B10","volume-title":"Advagraf Summary of Product Characteristics","year":"2010"},{"key":"B11","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1053\/j.ajkd.2022.01.001","article-title":"Special Considerations for Paxlovid Treatment Among Transplant Recipients With SARS-CoV-2 Infection","volume":"79","author":"Fishbane","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e14037","DOI":"10.1111\/tid.14037","article-title":"Saving Lives With Nirmatrelvir\/Ritonavir One Transplant Patient at a Time","volume":"25","author":"Belden","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1007\/s00467-022-05712-0","article-title":"Elevated Tacrolimus Levels After Treatment With Nirmatrelvir\/Ritonavir (Paxlovid) for COVID-19 Infection in a Child With a Kidney Transplant","volume":"38","author":"Young","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1150341","DOI":"10.3389\/fimmu.2023.1150341","article-title":"Optimizing the Use of Nirmatrelvir\/Ritonavir in Solid Organ Transplant Recipients With COVID-19: A Review of Immunosuppressant Adjustment Strategies","volume":"14","author":"Tang","year":"2023","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1111\/ajt.16997","article-title":"Effect of Nirmatrelvir\/Ritonavir on Calcineurin Inhibitor Levels: Early Experience in Four SARS-CoV-2 Infected Kidney Transplant Recipients","volume":"22","author":"Wang","year":"2022","journal-title":"Am J Transplant"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1111\/ajt.17140","article-title":"COVID-19 Therapeutics and Outcomes Among Solid Organ Transplant Recipients During the Omicron BA.1 Era","volume":"22","author":"Hedvat","year":"2022","journal-title":"Am J Transplant"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e14752","DOI":"10.1111\/ctr.14752","article-title":"Single\u2010Center Experience With Nirmatrelvir\/Ritonavir in Kidney Transplant Recipients on Tacrolimus Maintenance Immunosuppression","volume":"36","author":"Mecadon","year":"2022","journal-title":"Clin Transplant"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1016\/j.ekir.2022.08.026","article-title":"Safety, Efficacy, and Relapse of Nirmatrelvir-Ritonavir in Kidney Transplant Recipients Infected With SARS-CoV-2","volume":"7","author":"Devresse","year":"2022","journal-title":"Kidney Int Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1021\/jasms.2c00204","article-title":"A UPLC-MS\/MS Method for Plasma Biological Monitoring of Nirmatrelvir and Ritonavir in the Context of SARS-CoV-2 Infection and Application to a Case","volume":"33","author":"Guyon","year":"2022","journal-title":"J Am Soc Mass Spectrom"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1097\/TP.0000000000004394","article-title":"Nirmatrelvir\/Ritonavir Use with Tacrolimus in Lung Transplant Recipients: A Single-Center Case Series","volume":"107","author":"Dewey","year":"2023","journal-title":"Transplantation"},{"key":"B21","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.therap.2023.03.001","article-title":"Nirmatrelvir\/Ritonavir (Paxlovid\u00ae): French Pharmacovigilance Survey 2022","volume":"78","author":"Bihan","year":"2023","journal-title":"Therapies"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1016\/j.transproceed.2023.03.001","article-title":"Elevated Tacrolimus Blood Concentration Due to the Interaction With Nirmatrelvir\/Ritonavir During COVID-19 Treatment: A Case Report","volume":"55","author":"Cordero","year":"2023","journal-title":"Transplant Proc"},{"key":"B23","doi-asserted-by":"publisher","first-page":"ofac238","DOI":"10.1093\/ofid\/ofac238","article-title":"Supratherapeutic Tacrolimus Concentrations With Nirmatrelvir\/Ritonavir in Solid Organ Transplant Recipients Requiring Hospitalization: A Case Series Using Rifampin for Reversal","volume":"9","author":"Rose","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.12890\/2022_003528","article-title":"Paxlovid With Caution: Novel Case of Paxlovid-Induced Tacrolimus Toxicity in a Cardiac Transplant Patients","volume":"11","author":"Shah","year":"2022","journal-title":"Eur J Case Rep Intern Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/clpt.2011.164","article-title":"Determining the Time Course of CYP3A Inhibition by Potent Reversible and Irreversible CYP3A Inhibitors Using A Limited Sampling Strategy","volume":"90","author":"Katzenmaier","year":"2011","journal-title":"Clin Pharmacol Ther"}],"container-title":["Transplant International"],"original-title":[],"link":[{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/ti.2024.12360\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T04:11:27Z","timestamp":1711426287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/ti.2024.12360\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,26]]},"references-count":25,"alternative-id":["10.3389\/ti.2024.12360"],"URL":"https:\/\/doi.org\/10.3389\/ti.2024.12360","relation":{},"ISSN":["1432-2277"],"issn-type":[{"value":"1432-2277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,26]]},"article-number":"12360"}}